---
title: "Apimeds net loss widens to $20.17 million in Q2 2026; R&D expenses rise 47% to $959,742 vs year-ago quarter"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295973108.md"
description: "Apimeds reported a widened net loss of $20.17 million for Q2 2026, up from $2.66 million in the prior year period. Loss per share increased to $11.77. The significant deterioration was driven by a $13.89 million swing to other expenses, primarily due to a $13.18 million unrealized loss on digital assets, which constitute 89% of total assets. Additionally, R&D expenses rose 47% to nearly $960,000, and general and administrative costs more than doubled to $5.32 million due to settlement-related fees."
datetime: "2026-08-14T20:31:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295973108.md)
  - [en](https://longbridge.com/en/news/295973108.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295973108.md)
---

# Apimeds net loss widens to $20.17 million in Q2 2026; R&D expenses rise 47% to $959,742 vs year-ago quarter

-   Apimeds posted a net loss of USD 20.17 million for the quarter ended June 30, 2026, widening from USD 2.66 million. \* Loss per share widened to USD 11.77 from USD 2.57. \* Other expense swung to USD 13.89 million from other income of USD 1,711, driven by a USD 13.18 million unrealized digital-asset loss. \* General and administrative costs jumped to USD 5.32 million from USD 2.01 million, on settlement-related fees and transaction costs. \* Digital assets had a fair value of USD 116.74 million, representing 89% of total assets, with earnings volatility tied to fair-value changes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090120), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [APUS.US](https://longbridge.com/en/quote/APUS.US.md)

## Related News & Research

- [Xylem sets quarterly distribution at R$ 0.75 per unit for 3Q 2026](https://longbridge.com/en/news/296117630.md)
- [GE HealthCare declares Q3 2026 distribution of R$ 0.02 per unit](https://longbridge.com/en/news/296242723.md)
- [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md)
- [Jacktel to webcast Q2, H1 2026 results](https://longbridge.com/en/news/296198778.md)
- [Diageo announces BRL 0.32 per unit distribution for Q3 2026](https://longbridge.com/en/news/295964479.md)